11 false false false false false false false false false false true false false false false false false No description of principal activity 2024-04-01 Sage Accounts Production Advanced 2023 - FRS102_2023 286,875 286,875 130,877 130,877 130,877 xbrli:pure xbrli:shares iso4217:GBP 04588935 2024-04-01 2025-03-31 04588935 2025-03-31 04588935 2024-03-31 04588935 2023-04-01 2024-03-31 04588935 2024-03-31 04588935 2023-03-31 04588935 core:PlantMachinery 2024-04-01 2025-03-31 04588935 core:FurnitureFittings 2024-04-01 2025-03-31 04588935 bus:Director1 2024-04-01 2025-03-31 04588935 core:NetGoodwill 2025-03-31 04588935 core:LandBuildings 2024-03-31 04588935 core:PlantMachinery 2024-03-31 04588935 core:FurnitureFittings 2024-03-31 04588935 core:LandBuildings 2025-03-31 04588935 core:PlantMachinery 2025-03-31 04588935 core:FurnitureFittings 2025-03-31 04588935 core:WithinOneYear 2025-03-31 04588935 core:WithinOneYear 2024-03-31 04588935 core:ShareCapital 2025-03-31 04588935 core:ShareCapital 2024-03-31 04588935 core:RetainedEarningsAccumulatedLosses 2025-03-31 04588935 core:RetainedEarningsAccumulatedLosses 2024-03-31 04588935 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 04588935 core:Non-currentFinancialInstruments 2025-03-31 04588935 core:Non-currentFinancialInstruments 2024-03-31 04588935 core:LandBuildings 2024-03-31 04588935 core:PlantMachinery 2024-03-31 04588935 core:FurnitureFittings 2024-03-31 04588935 bus:SmallEntities 2024-04-01 2025-03-31 04588935 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 04588935 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 04588935 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 04588935 bus:FullAccounts 2024-04-01 2025-03-31 04588935 core:NetGoodwill 2024-04-01 2025-03-31
COMPANY REGISTRATION NUMBER: 04588935

MASTERS PHARMACY LIMITED

Filleted Unaudited Financial Statements

For the year ended

31 March 2025

MASTERS PHARMACY LIMITED

Statement of Financial Position

31 March 2025

| 2025 | 2024
Note | £ | £ | £

Fixed assets

Tangible assets | 6 |  | 388,407 | 396,291
Investments | 7 |  | 130,877 | 130,877
|  | --------- | ---------
|  | 519,284 | 527,168

Current assets

Stocks | 43,163 |  | 51,621
Debtors | 8 | 152,262 |  | 176,214
Cash at bank and in hand | 390,028 |  | 303,138
| --------- |  | ---------
| 585,453 |  | 530,973

Creditors: amounts falling due within one year | 9 | 418,780 |  | 414,199
| --------- |  | ---------
Net current assets |  | 166,673 | 116,774
|  | --------- | ---------
Total assets less current liabilities |  | 685,957 | 643,942
|  | --------- | ---------
Net assets |  | 685,957 | 643,942
|  | --------- | ---------

MASTERS PHARMACY LIMITED

Statement of Financial Position (continued)

31 March 2025

| 2025 | 2024
Note | £ | £ | £

Capital and reserves

Called up share capital |  | 2 | 2
Profit and loss account |  | 685,955 | 643,940
|  | --------- | ---------
Shareholders funds |  | 685,957 | 643,942
|  | --------- | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 3 December 2025 , and are signed on behalf of the board by:

Mr Murtaza Master
Director

Company registration number: 04588935

MASTERS PHARMACY LIMITED

Notes to the Financial Statements

Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 182 Vicarage Road, Oldbury, West Midlands, B68 8JB.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

| Goodwill | - | 5% At cost

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

| Plant and Machinery | - | 15% reducing balance
| Fixtures and Equipments | - | 20% reducing balance

Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 11 (2024: 11 ).
5. Intangible assets

| Goodwill
| £
Cost |
At 1 April 2024 and 31 March 2025 | 286,875
| ---------
Amortisation |
At 1 April 2024 and 31 March 2025 | 286,875
| ---------
Carrying amount |
At 31 March 2025 | –
| ---------
At 31 March 2024 | –
| ---------

6. Tangible assets

| Land and buildings | Plant and machinery | Fixtures and fittings | Total
| £ | £ | £ | £
Cost |  |  |  |
At 1 April 2024 | 323,537 | 136,015 | 128,207 | 587,759
Additions | – | – | 766 | 766
| --------- | --------- | --------- | ---------
At 31 March 2025 | 323,537 | 136,015 | 128,973 | 588,525
| --------- | --------- | --------- | ---------
Depreciation |  |  |  |
At 1 April 2024 | – | 83,854 | 103,306 | 187,160
Charge for the year | – | 7,824 | 5,134 | 12,958
| --------- | --------- | --------- | ---------
At 31 March 2025 | – | 91,678 | 108,440 | 200,118
| --------- | --------- | --------- | ---------
Carrying amount |  |  |  |
At 31 March 2025 | 323,537 | 44,337 | 20,533 | 388,407
| --------- | --------- | --------- | ---------
At 31 March 2024 | 323,537 | 52,161 | 24,901 | 400,599
| --------- | --------- | --------- | ---------

7. Investments

| Shares in participating interests
| £
Cost |
At 1 April 2024 and 31 March 2025 | 130,877
| ---------
Impairment |
At 1 April 2024 and 31 March 2025 | –
| ---------

Carrying amount |
At 31 March 2025 | 130,877
| ---------
At 31 March 2024 | 130,877
| ---------

8. Debtors

| 2025 | 2024
| £ | £
Trade debtors | 80,195 | 112,522
Other debtors | 72,067 | 63,692
| --------- | ---------
| 152,262 | 176,214
| --------- | ---------

9. Creditors: amounts falling due within one year

| 2025 | 2024
| £ | £
Trade creditors | 229,285 | 243,401
Corporation tax | 16,967 | 11,399
Social security and other taxes | 3,328 | –
Other creditors | 169,200 | 159,399
| --------- | ---------
| 418,780 | 414,199
| --------- | ---------